NCT06958315Active, not recruiting
Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study
An Observational Prospective Study to Assess the Effectiveness of Inclisiran(Leqvio®)in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spanish Clinical Practice:the INSPIRE Study
Source: ClinicalTrials.gov · Last updated 7 Aug 2026
Brief summary (registry, in English)
This study aims to address several key questions regarding the use of inclisiran in real-world clinical practice in Spain.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 219 (actual)
- First submitted
- 25 Apr 2025
- Start date
- 16 Jun 2025
- Primary completion date
- 1 May 2027
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Familial hypercholesterolaemia
- NCT number
- NCT06958315
What you commit to
- Study type: Observational
- Participants enrolled: 219
- From 16 Jun 2025 to the primary completion date, 1 May 2027
- 19 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- 1\. Participating in a clinical trial of a treatment that could modify LDL-C levels during the observational period of the study.
Who the study is looking for
- Aged ≥ 18 years.
- Written signed informed consent form (ICF).
- Patients with a confirmed clinical indication for inclisiran who have received the first dose of inclisiran, following clinical judgement, at least 2 months prior to the inclusion in the study.
- Available assessment of LDL-C levels (mg/dL) within 6 months before inclisiran initiation. The measurement of LDL-C levels must be done after one month of stable LLT and without any modification from the testing up to inclisiran initiation.
- Statin-intolerant patients are eligible if they had documented side effects on ≥2 statins, including one at the lowest dose.
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (19)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.